KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $12.1 million.

  • Castle Biosciences' Share-based Compensation fell 711.6% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 938.58%. This contributed to the annual value of $50.3 million for FY2024, which is 175.52% down from last year.
  • Per Castle Biosciences' latest filing, its Share-based Compensation stood at $12.1 million for Q3 2025, which was down 711.6% from $11.2 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Share-based Compensation ranged from a high of $13.5 million in Q1 2023 and a low of $4.8 million during Q2 2021
  • Its 5-year average for Share-based Compensation is $10.2 million, with a median of $11.2 million in 2025.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 21154.09% in 2021, then crashed by 1495.56% in 2025.
  • Quarter analysis of 5 years shows Castle Biosciences' Share-based Compensation stood at $6.9 million in 2021, then soared by 44.84% to $9.9 million in 2022, then rose by 18.94% to $11.8 million in 2023, then fell by 3.08% to $11.4 million in 2024, then increased by 5.78% to $12.1 million in 2025.
  • Its Share-based Compensation was $12.1 million in Q3 2025, compared to $11.2 million in Q2 2025 and $11.2 million in Q1 2025.